AstraZeneca PLC $AZN Shares Sold by Personal CFO Solutions LLC

Personal CFO Solutions LLC trimmed its stake in AstraZeneca PLC (NASDAQ:AZN) by 25.0% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,506 shares of the company’s stock after selling 5,496 shares during the quarter. Personal CFO Solutions LLC’s holdings in AstraZeneca were worth $1,153,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of AZN. Goldman Sachs Group Inc. increased its stake in AstraZeneca by 30.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock worth $1,003,124,000 after purchasing an additional 3,224,251 shares in the last quarter. Valeo Financial Advisors LLC boosted its holdings in shares of AstraZeneca by 14,797.3% in the second quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock worth $162,306,000 after buying an additional 2,307,047 shares during the period. Acadian Asset Management LLC boosted its holdings in shares of AstraZeneca by 2,389.9% in the second quarter. Acadian Asset Management LLC now owns 2,043,850 shares of the company’s stock worth $142,798,000 after buying an additional 1,961,764 shares during the period. American Century Companies Inc. increased its position in shares of AstraZeneca by 406.9% in the first quarter. American Century Companies Inc. now owns 2,020,629 shares of the company’s stock worth $148,517,000 after acquiring an additional 1,621,974 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in shares of AstraZeneca by 15.2% during the second quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock valued at $850,255,000 after acquiring an additional 1,605,133 shares during the period. 20.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on AZN shares. Jefferies Financial Group initiated coverage on shares of AstraZeneca in a research note on Monday, October 27th. They issued a “buy” rating for the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Trading Down 0.3%

AstraZeneca stock opened at $88.68 on Friday. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $90.27. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. The stock has a market cap of $275.03 billion, a P/E ratio of 33.34, a P/E/G ratio of 1.52 and a beta of 0.34. The company’s fifty day simple moving average is $82.77 and its 200-day simple moving average is $76.66.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.05. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business had revenue of $15.19 billion during the quarter, compared to analyst estimates of $14.75 billion. During the same period last year, the company earned $2.08 earnings per share. AstraZeneca’s quarterly revenue was up 12.0% compared to the same quarter last year. As a group, sell-side analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.